Date:		_	2022/11/03				_
Your Name:		_	Rongrong Fan	]			_
Manuscript Title:			[Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care ]				
Mar	nuscript Number (if k	nown):	APM-22-1058	]			-
In the interest of transparency, we ask you to disclose all content of your manuscript. "Related" means any relation affected by the content of the manuscript. Disclosure repindicate a bias. If you are in doubt about whether to list at The author's relationships/activities/interests should be depidemiology of hypertension, you should declare all relating that medication is not mentioned in the manuscript.				relation with for- sure represents a c to list a relationsh uld be defined bro all relationships w	profit or no commitmen nip/activity, adly. For e	ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.	
	em #1 below, report ne for disclosure is th			eported in this ma	nuscript w	ithout time limit. For all other items, the time	
				hom you have thi		Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time fram	me: Since the initia	al planning	of the work	
				ine. Since the initia			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Populari	ne dy was funded b ization Project f	by Special Science for the Constructio nce (2019ZK4029)		Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	ne dy was funded b ization Project f	by Special Science for the Constructio	n of	Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	ne dy was funded b ization Project f ve Hunan Provi	by Special Science for the Constructio nce (2019ZK4029)	n of	Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
Plea [⊠ ]	•	t to the following statement to indicate your agreeme	

Date:		. <del>-</del>	2022/11/03					
Your Name:			Xuying Li					
Manuscript Title:			Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care					
Mar	nuscript Number (if k	known):	APM-22-1058 ]					
con affe indi The epic that	tent of your manuscr cted by the content of cate a bias. If you ar author's relationship demiology of hyperte medication is not m	ript. "Rela of the mar re in doubt ps/activitie ension, you nentioned i	ted" means any relation inscript. Disclosure replator about whether to list a solution in the manuscript.	n with for-profit or no resents a commitme relationship/activity efined broadly. For e ionships with manuf	es/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.  example, if your manuscript pertains to the facturers of antihypertensive medication, even if without time limit. For all other items, the time			
			entities with whom yo hip or indicate none (ad		Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Sinc	e the initial planning	of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Popular		al Science onstruction of	Click the tab key to add additional rows.			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stu Popular	dy was funded by Specialization Project for the Cove Hunan Province (201	al Science onstruction of	Click the tab key to add additional rows.			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stu Popular	dy was funded by Specialization Project for the Cove Hunan Province (201	al Science onstruction of 9ZK4029)	Click the tab key to add additional rows.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
Plea [⊠ ]	•	t to the following statement to indicate your agreeme	

Date:		_	2022/11/03					
Your Name:			Siyu Yang					
Manuscript Title:			Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care					
Mar	nuscript Number (if k	known):	APM-22-1058					
contaffe indicated and the contact and the con	tent of your manuscr cted by the content of cate a bias. If you are author's relationship lemiology of hyperte medication is not m	ript. "Relat of the man e in doubt os/activities ension, you entioned in	ed" means any relation uscript. Disclosure reprate to list a solution whether to list a solution and the destruction the manuscript.	with for-profit or no resents a commitme relationship/activity efined broadly. For e ionships with manuf	es/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.  example, if your manuscript pertains to the acturers of antihypertensive medication, even if without time limit. For all other items, the time			
			entities with whom you		Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Since	e the initial planning	of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Popularia	ne ly was funded by Specia zation Project for the Co ve Hunan Province (201	onstruction of	Click the tab key to add additional rows.			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	ly was funded by Specia zation Project for the Co ve Hunan Province (201	onstruction of				
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	ly was funded by Specia zation Project for the Co ve Hunan Province (201	onstruction of 9ZK4029)				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
Plea [⊠ ]	•	t to the following statement to indicate your agreeme	

Date:		_	2022/11/03				
Your Name:			Xiaofan Bu				
Manuscript Title:			Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care				
Mar	nuscript Number (if k	known):	APM-22-1058	]			_
contaffe indicated and the contact and the con	tent of your manuscr cted by the content of cate a bias. If you are author's relationship lemiology of hyperte medication is not m	ript. "Related of the mande in doubt os/activities ension, you dentioned in all suppor	ted" means any uscript. Disclos about whether s/interests show should declare in the manuscript to the work re	relation with for-produce represents a control to list a relationship all be defined broad all relationships with	rofit or no ommitmer p/activity, dly. For e th manufa	s/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.  example, if your manuscript pertains to the acturers of antihypertensive medication, even if ithout time limit. For all other items, the time	
				hom you have this none (add rows as i		Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time fran	me: Since the initial	planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Populari	dy was funded b zation Project fo	oy Special Science or the Construction nce (2019ZK4029)	of	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	dy was funded b zation Project fo	or the Construction			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	dy was funded b zation Project fo ve Hunan Provin	or the Construction nce (2019ZK4029)			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
Plea [⊠ ]	•	t to the following statement to indicate your agreeme	

Date:		_	2022/11/03					
Your Name:		-	Yongyi Chen				_	
Manuscript Title:			[Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care ]					
Mar	nuscript Number (if k	known):	APM-22-1058	]			_	
contaffe indicated and the contact and the con	tent of your manuscr cted by the content of cate a bias. If you are author's relationship lemiology of hyperte medication is not m	ript. "Rela of the mar e in doubt os/activitie ension, you entioned i	ted" means any nuscript. Disclos about whether es/interests shou should declare in the manuscrip	relation with for-pare represents a control to list a relationship wild be defined brown all relationships wort.	profit or no commitmer nip/activity, adly. For e vith manufa	es/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.  example, if your manuscript pertains to the acturers of antihypertensive medication, even if without time limit. For all other items, the time		
				rhom you have thi none (add rows as		Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time fran	me: Since the initia	al planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Popular	one dy was funded b ization Project fo	by Special Science or the Construction nce (2019ZK4029)		Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stu	one dy was funded b ization Project fo	by Special Science or the Construction	n of	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stu	one dy was funded b ization Project fo ive Hunan Provin	oy Special Science or the Construction nce (2019ZK4029)	n of	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
Plea [⊠ ]	•	t to the following statement to indicate your agreeme	

Date:		_	2022/11/03					
Your Name:		<del>-</del>	Ying Wang					
Manuscript Title:		_	igl[ Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care $igr]$					
Mar	nuscript Number (if k	(nown):	APM-22-1058					
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activiti			ted" means any luscript. Disclost about whether the s/interests shou	relation with for-pro ure represents a com to list a relationship/ Id be defined broadl	fit or no nmitmer activity/ y. For e	s/interests listed below that are related to the t-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.  xample, if your manuscript pertains to the		
	medication is not m				i manuta	acturers of antihypertensive medication, even if		
	em #1 below, report ne for disclosure is th			ported in this manus	script wi	thout time limit. For all other items, the time		
			all entities with whom you have this nship or indicate none (add rows as needed)			Specifications/Comments (e.g., if payments were made to you or to your institution)		
						of the work		
			Time fram	ne: Since the initial pl	lanning o	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Populari	ne dy was funded by zation Project fo	y Special Science or the Construction of the C	f	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stud	ne dy was funded by zation Project fo ve Hunan Provin	y Special Science or the Construction of oce (2019ZK4029)	f	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
Plea [⊠ ]	•	t to the following statement to indicate your agreeme	

Date:		<u>-</u>	11/3/2022				
Your Name:		-	Cuiling Qiu				
Manuscript Title:			[Development of a prognostic nomogram based on objective blood test data for patients with advanced cancer undergoing palliative care ]				
Mar	nuscript Number (if I	known):	APM-22-105	se ]			
contaffe indicated and the contact and the con	tent of your manusci cted by the content cate a bias. If you ar author's relationship demiology of hyperte medication is not m	ript. "Rela of the mar e in doubt ps/activitie ension, you eentioned i	ted" means a nuscript. Disc about wheth es/interests sh i should decla in the manusc	iny relation with closure represent per to list a relation nould be defined are all relationshi cript.	for-profit or not as a commitment on ship/activity.  I broadly. For each of the ship with manuform of the ship with manuform of the ship with manuform.	es/interests listed below that are related to the ot-for-profit third parties whose interests may be nt to transparency and does not necessarily /interest, it is preferable that you do so.  example, if your manuscript pertains to the acturers of antihypertensive medication, even if without time limit. For all other items, the time	
				whom you have te none (add rov		Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time f	rame: Since the i	initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Popular	dy was funde ization Projec	d by Special Sciel et for the Constru ovince (2019ZK40	nce action of	Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stu Popular	dy was funde ization Projec	d by Special Scie et for the Constru ovince (2019ZK40	nce action of	Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This stu Popular	dy was funder ization Projec ive Hunan Pro	d by Special Scie et for the Constru ovince (2019ZK40	nce Iction of 029)	Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	[⊠ ] None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	[⊠ ] None	
6	Payment for expert testimony	[⊠ ] None	
7	Support for attending meetings and/or travel	[⊠ ] None	
8	Patents planned, issued or pending	[⊠ ] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠ ] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠ ] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ ] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠ ] None	
13	Other financial or non-financial interests	[⊠ ] None	
		t to the following statement to indicate your agreeme	